乳腺癌新辅助化疗的研究进展
摘要
近年来,新辅助化疗治疗乳腺癌的概念引起了肿瘤学界极大的兴趣。一系列正在进行的临床研究都希望这一新疗法能够从总体上增加疗效。新的化疗药物、新的影像学检查工具及某些生物学因子正日益引起广大学者的密切关注。基因表达谱也有望对新辅助化疗反应作出预测。本文对以上诸方面分别作了介绍。
出处
《国外医学（外科学分册）》
2005年第4期286-291,共6页
Foreign Medical Sciences(section of Surgery)
参考文献30
-
1Bhalla K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol, 1998, 25 (Suppl 3): 19-24.
-
2Garces CA, Cance WG. Neoadjuvant chemotherapy of breast cancer. Am Surg, 2004, 70(7): 565-569.
-
3Dash N, Chafin SH, Johnson RR, et al. Usefulness of tissue marker clips in patients undergoing neoadjuvant chemotherapy for breast cancer. AJR Am J Roentgenol, 1999, 173(4): 911-917.
-
4Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women recciving neoadjuvant chemotherapy. Eur Radiol, 2004, 14(8): 1371-1379.
-
5Hung WK, Lau Y, Chan CM, et al. Experience of neoadjuvant chemotherapy for breast cancer at a public hospital: retrospective study. Hong Kong Med J, 2000, 6(3): 265-268.
-
6Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kineics and growth of metastases. Cancer Res, 1983, 43(4): 1488-1492.
-
7Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced brast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg, 2002, 236(3): 295-303.
-
8Valero V, Holmes FA, Walters RS, et al. Phase Ⅱ trial of docetaxel: a new, highlyeffective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol, 1995, 13(12): 2886-2894.
-
9Bear HD, Anderson S, Brown A, et al. The effect on ttmor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphmmide: preliminary reualts from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 2003, 21(22): 4165-4174.
-
10Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol, 2002, 9(3): 228-234.
-
1徐松涛,邵雪峰,蒋挺,刘锋.EZH2和Ki67蛋白在膀胱移行细胞癌中的表达及意义[J].中国现代医药杂志,2010,12(11):72-74. 被引量：2
-
2刘映.C-erbB-2、Ki67及GST-π在乳腺癌中的表达及相互关系[J].中国现代医药杂志,2006,8(6):9-12. 被引量：4
-
3崔猛胜,刘秉义,季德刚,李晨玉.组织蛋白酶D在乳腺良、恶性病变中的表达及意义[J].中国免疫学杂志,1999,15(5):221-222. 被引量：2
-
4张萍,周美珍.乳腺癌分子生物学预后指标[J].中国临床保健杂志,2005,8(3):279-282.
-
5谭新华(综述),袁卫平(综述).乳腺癌的新辅助化疗[J].中国医学文摘（肿瘤学）,2007,21(3):253-255.
-
6李成贻,江川,林茂华,汤宁文,赵桂斌,张哲.新辅助化疗对局部晚期乳腺癌ER、PR、c-erbB-2的影响[J].中国医药指南,2010,8(34):186-188. 被引量：2
-
7张杰,邵志敏,沈镇宙.乳腺癌生物学预后因子的研究进展[J].中国癌症杂志,2002,12(5):465-469.
-
8金艳.彩色多普勒检测女性乳腺癌22例[J].中国中医药现代远程教育,2011,9(7):86-86.
-
9温怀玺.生物学因子预测乳腺癌新辅助化疗疗效新进展[J].生物技术世界,2014,11(2):97-97.
-
10刘运江,刘现义,刘巍,单保恩.hMAM检测乳腺癌骨髓微转移及其意义[J].中国肿瘤临床,2006,33(10):549-551. 被引量：5
